---
figid: PMC4655250__WJEM-5-206-g002
figtitle: 'Endoplasmic reticulum stress-mediated pathways to both apoptosis and autophagy:
  Significance for melanoma treatment'
organisms:
- NA
pmcid: PMC4655250
filename: WJEM-5-206-g002.jpg
figlink: /pmc/articles/PMC4655250/figure/F2/
number: F2
caption: 'Proposed models for the mechanistic role of endoplasmic reticulum stress
  in the modulation of the anti-tumor efficiency of vemurafenib, dabrafenib and trametenib
  in melanoma patients harboring activating neuroblastoma RAS viral (v-ras) oncogene
  homolog or rapidly accelerated fibrosarcoma murine sarcoma viral (v-raf) oncogene
  homolog B mutations. The main function of MC1R, TRK on melanoma cell is to transmit
  extracellular signaling that is essential for the activation of RAS-RAF-MEK-ERK
  and PI3K-AKT-mTOR pathways to mediate various cellular functions including melanoma
  initiation, progression and resistance. Thus, the exposure of melanoma (BRAFmt and
  NRASmt) cells to either Vemurafenib, Dabrafenib or Trametenib, respectively, results
  in inhibition of MC1R, cKIT and TRK-mediated activation of RAS-RAF-MEK-ERK and PI3K-AKT-mTOR
  pathways. As consequence the inhibition of RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways
  results in the execution melanoma cell death via mechanism-mediated by ER stress-dependent
  pathways including PERK-eIF2α-ATF4-ATF3-CHOP-Bim pathway. NRAS: Neuroblastoma Rat
  Sarcoma viral (v-ras) oncogene homolog; BRAF: Rapidly Accelerated Fibrosarcoma murine
  sarcoma viral (v-raf) oncogene homolog B; MC1R: Melanocortin 1 receptor; TRK: CKIT
  and receptor tyrosine kinase; PI3K: Phosphatidylinositol-4,5-bisphosphate 3-kinase;
  AKT: Protein kinase B.'
papertitle: 'Endoplasmic reticulum stress-mediated pathways to both apoptosis and
  autophagy: Significance for melanoma treatment.'
reftext: Mohamed Hassan, et al. World J Exp Med. 2015 Nov 20;5(4):206-217.
year: '2015'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9606004
figid_alias: PMC4655250__F2
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC4655250__F2
ndex: 5de37e18-dedd-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4655250__WJEM-5-206-g002.html
  '@type': Dataset
  description: 'Proposed models for the mechanistic role of endoplasmic reticulum
    stress in the modulation of the anti-tumor efficiency of vemurafenib, dabrafenib
    and trametenib in melanoma patients harboring activating neuroblastoma RAS viral
    (v-ras) oncogene homolog or rapidly accelerated fibrosarcoma murine sarcoma viral
    (v-raf) oncogene homolog B mutations. The main function of MC1R, TRK on melanoma
    cell is to transmit extracellular signaling that is essential for the activation
    of RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways to mediate various cellular functions
    including melanoma initiation, progression and resistance. Thus, the exposure
    of melanoma (BRAFmt and NRASmt) cells to either Vemurafenib, Dabrafenib or Trametenib,
    respectively, results in inhibition of MC1R, cKIT and TRK-mediated activation
    of RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways. As consequence the inhibition of
    RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways results in the execution melanoma cell
    death via mechanism-mediated by ER stress-dependent pathways including PERK-eIF2α-ATF4-ATF3-CHOP-Bim
    pathway. NRAS: Neuroblastoma Rat Sarcoma viral (v-ras) oncogene homolog; BRAF:
    Rapidly Accelerated Fibrosarcoma murine sarcoma viral (v-raf) oncogene homolog
    B; MC1R: Melanocortin 1 receptor; TRK: CKIT and receptor tyrosine kinase; PI3K:
    Phosphatidylinositol-4,5-bisphosphate 3-kinase; AKT: Protein kinase B.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MC1R
  - KIT
  - PTEN
  - HSPA5
  - EIF2AK3
  - BRAF
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - ATF3
  - MITF
  - AKT1
  - AKT2
  - AKT3
  - ATF4
  - DDIT3
  - MTOR
  - BCL2L11
  - CDKN1A
  - TCEAL1
  - NSG1
  - H3P16
  - Trametinib
  - Dabrafenib
  - Cancer
---
